The present invention relates to tissue ablation devices generally, and more particularly to devices adapted to ablate lines of tissue, for example for use in conjunction with an electrosurgical version of the Maze procedure. More particularly, the invention relates to an ablation device that aids in the measurement of tissue thickness and monitoring the transmurality of lesions.
Various types of electrophysiology devices are used for ablating tissue. Typically, such devices include a conductive tip or blade which serves as one electrode in an electrical circuit which is completed via a grounding electrode coupled to the patient. With sufficiently high levels of electrical energy between the two electrodes, heat is generated which is sufficient to denature proteins within the tissue and cause cell death.
It is well known that by controlling the energy level, the amount of heat generated and degree of tissue damage can also be controlled. High levels of voltage can cut and remove tissue (i.e. electrosurgery), while lower levels will simply create sufficient heat to cause cell damage, but leave the structure intact and block electrical pathways within the tissue. Irrigation of the electrodes with saline or other conductive fluid can decrease the interface impedance, cool the tissue, and allow for a greater lesion depth. It is also know that a bipolar system (where the grounding electrode is in close proximity to the conductive tip) can create narrower and deeper lesions. At the limit, the grounding electrode is in the same dimension as the conductive tip, and both electrodes are used to create the lesion.
A bipolar ablation design may be created by integrating the electrode into the jaws of a hemostat (or forceps) like device. Mounting two electrodes onto the jaws of a forceps results in a tool that can clamp and ablate the tissue between the jaws.
A wide variety of surgical procedures involve ablation of selected tissue. One such procedure is the Maze procedure, which is a surgical operation for patients with atrial fibrillation that is resistant to medical treatment. In the conventional version of this procedure, incisions are created in the right and left atria to produce an orderly passage of the electrical impulse from the sino-atrial node (SA node) to the atrial-ventricular node (AV node). Blind passageways are also created to suppress reentry cycles. Ablation of cardiac conduction pathways in the region of tissue where electrical signals are malfunctioning is now being used to replace surgical incisions in the Maze procedure. Ablation is also used therapeutically with other organ tissues, such as the lungs, liver, prostate, and uterus. Ablation may also be used in treatment of disorders, such as tumors, cancers, or undesirable growths. There are various types of ablation devices that are in use and in development that are intended for use in the Maze procedure.
Sometimes ablation is necessary only at discrete positions along the tissue. At other times, ablation is desired along a line, called linear ablation. This is the case for atrial fibrillation, where the aim is to reduce the total mass of contiguous (electrically connected) atrial tissue below a threshold believed to be critical for sustaining multiple reentrant wavelets. Linear lesions are created between electrically non-conductive anatomic landmarks to reduce the contiguous atrial mass. One way of accomplishing linear ablation is to use a pair of bipolar electrosurgical forceps having jaws with an elongated electrode or series of electrodes used to apply energy to tissue for ablation purposes. One embodiment of this approach is described in U.S. patent Publication No. 2003/0171745, published Sep. 11, 2003, and titled “Ablation System and Method of Use,” which is incorporated herein by reference in its entirety.
In conjunction with the use of electrosurgical ablation devices, various control mechanisms have been developed to control delivery of ablation energy to achieve the desired result of ablation (killing of cells at the ablation site while leaving the basic structure of the organ to be ablated intact). Additionally, there has been substantial work done toward assuring that the ablation procedure is complete, i.e. that the ablation extends through the thickness of the tissue to be ablated, before terminating application of ablation energy. This desired result is referred to as “transmural” ablation. Non-transmural lesions may be capable of propagating a depolarization wave form, or action potential and may not be effective in treating an arrhythmia. One embodiment of a system for assessing the transmurality of an ablation lesion is described in U.S. patent Publication No. 2003/0195384, published Oct. 16, 2003, and titled “System and Method for Assessing Transmurality of Ablation Lesions,” which is incorporated herein by reference in its entirety.
One challenge associated with ablation procedures relates to determining the proper energy to apply to the tissue and duration of application of that energy in order to achieve the desired transmurality. One approach is to estimate tissue thickness and then to consult a look-up table to determine an experimentally determined energy and duration associated with that thickness. However, such an approach requires an accurate assessment of tissue thickness, which may also present a challenge. Further, depending on the type of device used to apply ablation energy to the tissue, further variables may be introduced. For example, when using a hemostat type device, the pressure between the jaws is a function of the force applied to the handles any may vary depending on the person holding the device. Such variability impacts the most effective treatment time and energy.
The design challenge with any ablation device, and in particular with a hemostat type device, is to create a lesion having consistent quality, in particular a continuous linear lesion when engaging in the Maze procedure. Further, it is desirable to create a lesion that is not too wide and that may be created in the least amount of time. Further, a challenge in the creation of such a device is to reduce the variability based upon the user such that a device may be used by various users with consistent results.
Accordingly, there is a need for an ablation device that is configured to permit a consistent application of appropriate force at the tissue site when in use. Further, there is a need for a device configured to permit real time assessment of lesion transmurality while in use. Further still, there is a need for an ablation device having the ability to aid in the determination of ablation parameters, such as degree of applied force, time of treatment, and treatment energy.
It would be desirable to provide a system and/or method that provides one or more of these or other advantageous features. Other features and advantages will be made apparent from the present specification. The teachings disclosed herein extend to those embodiments that fall within the scope of the appended claims, regardless of whether they accomplish one or more of the aforementioned needs.
The invention relates to a tissue ablation system having a handle and an ablation head coupled to the handle. The ablation head has a first jaw and a second jaw and an ablative element coupled to at least one of the first and second jaws. A thickness measurement device is coupled to the ablation head. The thickness measurement device indicates a distance separating the first and second jaws.
The invention further relates to a tissue ablation system having a handle and an ablation head coupled to the handle. The ablation head has a first jaw and a second jaw and an ablative element coupled to at least one of the first and second jaws. A force measurement device is coupled to the ablation head. The force measurement device indicates the force being applied by the first and second jaws on a piece of tissue disposed between the first and second jaws.
The invention further relates to a tissue ablation system having a handle and an ablation head coupled to the handle. The ablation head has a first jaw and a second jaw and an ablative element coupled to at least one of the first and second jaws. A strain measurement device is coupled to the ablation head. The strain measurement device indicates the strain resulting in a piece of tissue disposed between the first and second jaws when a stress is applied to the tissue.
The invention further relates to a method of assessing the transmurality of an ablation lesion in a piece of tissue during the performance of a surgical ablation procedure. The method includes the steps of applying a stress to the piece of tissue and calculating a strain in the tissue resulting from the application of the stress. The method further includes the step of determining the degree of transmurality of the ablation lesion based upon the strain and the stress.
The invention further relates to a method of ablating tissue. The method includes the steps of providing a bipolar ablation device having a pair of jaws, the jaws having one or more ablation electrodes, inserting the tissue between the jaws, and closing the jaws until the jaws engage the tissue. The method further includes the steps of measuring a thickness of the tissue by determining the distance between the jaws, selecting a jaw force, selecting an electrode energy, and selecting a time of energy application. The method further includes the steps of applying the selected jaw force to the tissue, energizing the one or more ablation electrodes to apply the selected electrode energy, and deenergizing the one or more ablation electrodes after the selected time has elapsed.
The invention is capable of other embodiments and of being practiced or carried out in various ways. Alternative exemplary embodiments relate to other features and combinations of features as may be generally recited in the claims.
The invention will become more fully understood from the following detailed description, taken in conjunction with the accompanying drawings, wherein like reference numerals refer to like elements, in which:
Referring to
Further referring to
Referring to
Further referring to
Further referring to
Although thickness gauge 40 is shown as a potentiometer or rheostat in
Referring to
The force meter 50 may provide a direct indication of the force being applied between the electrodes 28 or may alternatively provide an electronic signal representative of the force to another instrument, such as generator 22, which may then convert the electronic signal into a reading representative of the force being applied. In one embodiment, the jaws 24, 26 are closed by depressing trigger 16 (see
Referring to
Referring to
In order to access the tissue to be ablated, a surgeon must first open an aperture into a patient's body. In the performance of a Maze procedure, access to the patient's heart may be provided via an open chest, such as utilizing a median sternotomy. Alternatively, access to the heart may be provided via a minimally invasive approach, such as with endoscopic tools on a “closed” chest, using one or more small incisions or ports. The Maze procedure may be performed on a beating heart, or on a stopped heart, requiring the use of a heart lung machine to place the patient on cardiopulmonary bypass. The locations of the lesions made in the performance of a Maze procedure, as well as methods of accessing the heart, are known in the art.
In order to create a lesion, the surgeon inserts a selected portion of tissue 70 between jaws 24, 26 and closes the jaws on the tissue 70 using an appropriate amount of force. The jaws may be closed utilizing the trigger 16 (see
Prior to selecting the ablation parameters such as RF energy, force, and time, the surgeon may wish to know the tissue thickness. The thickness gauge 40 may be utilized to provide the thickness parameter by closing the jaws 24, 26 over the selected portion of tissue 70 and providing a visual indication of or signal representative of the thickness of tissue 70.
After determining the thickness of tissue 70, the surgeon may apply an appropriate amount of force using jaws 24, 26 prior to engaging electrodes 28. In order to provide accuracy in the amount of force applied, the force meter 50 of the present invention may be utilized to measure the force being applied. The amount of force may be visually read by the surgeon or may be provided in an electronic signal representative of the force to a control unit such as generator 22.
After closing the jaws 24, 26 on tissue 70 at the appropriate degree of force, the surgeon may lock the jaws into place at that degree of force utilizing locking mechanism 18. Alternatively, robotic control of the jaws may be provided by a control device, such as generator 22, rather than a manual locking mechanism 18. At this point, the surgeon may engage linear electrodes 28 to begin the creation of an ablation lesion in tissue 70. During the application of RF energy to create the ablation lesion, saline may be applied to the ablation area between electrodes 28 to cool the tissue 70. Saline may be provided to jaws 24, 26 via a saline irrigation line connected to a saline source.
Once an RF energy and force of application have been selected and the tissue thickness has been determined, a surgeon may determine the time of energy application necessary to accomplish the goal of a transmural lesion. The time may be selected from experimental results for a particular type of tissue. Particularly when performing a Maze procedure, it is desirable to select the proper amount of time to ensure lesion transmurality, as a non-transmural ablation may not accomplish the goal of the procedure, and applying energy for too much time may damage the tissue more than necessary. Once the time of energy application has been determined, the surgeon may activate the electrodes 28 to ablate the tissue 70 between jaws 24, 26. After a transmural lesion has been created, the surgeon opens the jaws 24, 26 and repositions the bipolar ablation device to another region of tissue or removes the device from the patient's body and completes the procedure.
Although a precise tissue thickness measurement and application of force aids in accurately determining the amount of time necessary to create a transmural lesion, it may be beneficial to provide an indicator of lesion transmurality to ensure success of the procedure. Visual assessment of the tissue to determine transmurality may be inconvenient or impossible depending on the location of the tissue being ablated and the type of ablation device. Methods of assessing the transmurality of ablation lesions have been disclosed, such as the temperature assessment method disclosed in U.S. patent Publication No. 2003/0195384.
According to one embodiment of the invention, the bipolar ablation device 10 provides a method of assessing lesion transmurality. The method may be utilized while the electrodes are energized to provide a real time assessment of lesion transmurality or may be utilized after electrodes have been utilized to create a lesion, to ensure the proper depth of ablation. It is known that ablated tissue exhibits a different strain for a given amount of stress than does non-ablated tissue. Referring to
As described above, certain embodiments of the present invention are described as having a strain measurement device, such as strain gauge 60, and a force measurement device such as force meter 50. These elements may be combined to provide the information necessary to utilize stress versus strain data to determine lesion transmurality. A given amount of stress may be applied to the tissue utilizing force meter 50 as an indicator of the force being applied over the area of the jaws. Alternatively, the selected amount of stress may be applied automatically using a control device such as generator 22. The resultant strain may be directly measured using strain gauge 60, but may also be calculated using thickness gauge 40 to calculate the change in thickness resultant from the applied stress versus the original thickness of the tissue.
The strain measurement may be quickly performed during a procedure while the electrodes are activated if desired. If this is the case, a control device, such as generator 22, may be programmed to perform real time assessments of lesion transmurality and automatically cease the application of RF energy through electrodes 28 when lesion transmurality has been accomplished. Further, stress versus strain curves for a number of degrees of lesion transmurality may be generated and programmed into generator 22 such that the user may be provided a real time indication of depth of ablation as a procedure is being performed.
While the concepts of measuring tissue thickness, force application, and tissue strain are described with respect to a bipolar ablation device, such concepts may be useful when applied to other types of ablation devices such as an electrocautery device, an electrosurgical device, an ablation paddle, and an ablation wire, among other types of devices. A set up similar to that shown in
The bipolar ablation device and system may be used in procedures requiring tissue ablation in the heart as described herein. However, the ablation device and system may also be used on other tissues (e.g. lungs, liver, prostate, etc.) and in other types of surgical procedures that require tissue ablation.
The generator depicted in
While the detailed drawings and specific examples given herein describe various exemplary embodiments, they serve the purpose of illustration only. It is to be understood that the invention is not limited in its application to the details of construction and the arrangements of components set forth in the preceding description or illustrated in the drawings. For example, in various embodiments described in this application, a force measurement device, a thickness measurement device, and a strain measurement device are described. These may be used separately on devices, or in various combinations as desired. Furthermore, other substitutions, modifications, changes, and omissions may be made in the design, operating conditions, and arrangements of the exemplary embodiments without departing from the scope of the invention as expressed in the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
3736936 | Basiulis et al. | Jun 1973 | A |
3807403 | Stumpf et al. | Apr 1974 | A |
3823575 | Parel | Jul 1974 | A |
3823718 | Tromovitch | Jul 1974 | A |
3827436 | Stumpf et al. | Aug 1974 | A |
3830239 | Stumpf | Aug 1974 | A |
3859986 | Okada et al. | Jan 1975 | A |
3862627 | Hans, Sr. | Jan 1975 | A |
3886945 | Stumpf et al. | Jun 1975 | A |
3907339 | Stumpf et al. | Sep 1975 | A |
3910277 | Zimmer | Oct 1975 | A |
3913581 | Ritson et al. | Oct 1975 | A |
3924628 | Droegemueller et al. | Dec 1975 | A |
4018227 | Wallach | Apr 1977 | A |
4022215 | Benson | May 1977 | A |
4061135 | Widran et al. | Dec 1977 | A |
4063560 | Thomas et al. | Dec 1977 | A |
4072152 | Linehan | Feb 1978 | A |
4082096 | Benson | Apr 1978 | A |
4207897 | Lloyd et al. | Jun 1980 | A |
4248224 | Jones | Feb 1981 | A |
4275734 | Mitchiner | Jun 1981 | A |
4278090 | van Gerven | Jul 1981 | A |
4377168 | Rzasa et al. | Mar 1983 | A |
4519389 | Gudkin et al. | May 1985 | A |
4598698 | Siegmund | Jul 1986 | A |
4601290 | Effron et al. | Jul 1986 | A |
4664110 | Schanzlin | May 1987 | A |
4736749 | Lundback | Apr 1988 | A |
4779611 | Grooters et al. | Oct 1988 | A |
4802475 | Weshahy | Feb 1989 | A |
4815470 | Curtis et al. | Mar 1989 | A |
4872346 | Kelly-Fry et al. | Oct 1989 | A |
4916922 | Mullens | Apr 1990 | A |
4917095 | Fry et al. | Apr 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4946460 | Merry et al. | Aug 1990 | A |
5013312 | Parins et al. | May 1991 | A |
5029574 | Shimamura et al. | Jul 1991 | A |
5044165 | Linner et al. | Sep 1991 | A |
5078713 | Varney | Jan 1992 | A |
5080102 | Dory | Jan 1992 | A |
5080660 | Buelna | Jan 1992 | A |
5100388 | Behl et al. | Mar 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5147355 | Friedman et al. | Sep 1992 | A |
5178133 | Pena | Jan 1993 | A |
5207674 | Hamilton | May 1993 | A |
5217860 | Fahy et al. | Jun 1993 | A |
5222501 | Ideker et al. | Jun 1993 | A |
5224943 | Goddard | Jul 1993 | A |
5228923 | Hed | Jul 1993 | A |
5231995 | Desai | Aug 1993 | A |
5232516 | Hed | Aug 1993 | A |
5254116 | Baust et al. | Oct 1993 | A |
5263493 | Avitall | Nov 1993 | A |
5269291 | Carter | Dec 1993 | A |
5275595 | Dobak, III | Jan 1994 | A |
5277201 | Stern | Jan 1994 | A |
5281213 | Milder et al. | Jan 1994 | A |
5281215 | Milder | Jan 1994 | A |
5295484 | Marcus et al. | Mar 1994 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5309896 | Moll et al. | May 1994 | A |
5316000 | Chapelon et al. | May 1994 | A |
5317878 | Bradshaw et al. | Jun 1994 | A |
5318525 | West et al. | Jun 1994 | A |
5322520 | Milder | Jun 1994 | A |
5323781 | Ideker et al. | Jun 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5324284 | Imran | Jun 1994 | A |
5324286 | Fowler | Jun 1994 | A |
5334181 | Rubinsky et al. | Aug 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5342357 | Nardella | Aug 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5353783 | Nakao et al. | Oct 1994 | A |
5354258 | Dory | Oct 1994 | A |
5361752 | Moll et al. | Nov 1994 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5395033 | Byrne et al. | Mar 1995 | A |
5396887 | Imran | Mar 1995 | A |
5397304 | Truckai | Mar 1995 | A |
5400770 | Nakao et al. | Mar 1995 | A |
5400783 | Pomeranz et al. | Mar 1995 | A |
5403309 | Coleman et al. | Apr 1995 | A |
5403311 | Abele et al. | Apr 1995 | A |
5405376 | Mulier et al. | Apr 1995 | A |
5409483 | Campbell et al. | Apr 1995 | A |
5423807 | Milder | Jun 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5427119 | Swartz et al. | Jun 1995 | A |
5431645 | Smith et al. | Jul 1995 | A |
5431649 | Mulier et al. | Jul 1995 | A |
5433708 | Nichols et al. | Jul 1995 | A |
5435308 | Gallup et al. | Jul 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5437664 | Cohen et al. | Aug 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5450843 | Moll et al. | Sep 1995 | A |
5452582 | Longsworth | Sep 1995 | A |
5452733 | Sterman et al. | Sep 1995 | A |
5456682 | Edwards et al. | Oct 1995 | A |
5462545 | Wang et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5469853 | Law et al. | Nov 1995 | A |
5472876 | Fahy | Dec 1995 | A |
5478309 | Sweezer et al. | Dec 1995 | A |
5478330 | Imran et al. | Dec 1995 | A |
5486193 | Bourne et al. | Jan 1996 | A |
5487385 | Avitall | Jan 1996 | A |
5487757 | Truckai et al. | Jan 1996 | A |
5496312 | Klicek | Mar 1996 | A |
5497774 | Swartz et al. | Mar 1996 | A |
5498248 | Milder | Mar 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5516505 | McDow | May 1996 | A |
5520682 | Baust et al. | May 1996 | A |
5522870 | Ben-Zion | Jun 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5542928 | Evans et al. | Aug 1996 | A |
5545195 | Lennox et al. | Aug 1996 | A |
5545200 | West et al. | Aug 1996 | A |
5549661 | Kordis et al. | Aug 1996 | A |
5555883 | Avitall | Sep 1996 | A |
5558671 | Yates | Sep 1996 | A |
5560362 | Sliwa, Jr. et al. | Oct 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5569241 | Edwards | Oct 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5573532 | Chang et al. | Nov 1996 | A |
5575766 | Swartz et al. | Nov 1996 | A |
5575788 | Baker et al. | Nov 1996 | A |
5575810 | Swanson et al. | Nov 1996 | A |
5578007 | Imran | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5584872 | LaFontaine et al. | Dec 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5590657 | Cain et al. | Jan 1997 | A |
5595183 | Swanson et al. | Jan 1997 | A |
5607462 | Imran | Mar 1997 | A |
5609151 | Mulier et al. | Mar 1997 | A |
5617854 | Munsif | Apr 1997 | A |
5630837 | Crowley | May 1997 | A |
5637090 | McGee et al. | Jun 1997 | A |
5643197 | Brucker et al. | Jul 1997 | A |
5653692 | Masterson et al. | Aug 1997 | A |
5656029 | Imran et al. | Aug 1997 | A |
5658278 | Imran et al. | Aug 1997 | A |
5671747 | Connor | Sep 1997 | A |
5673695 | McGee et al. | Oct 1997 | A |
5673704 | Marchlinski et al. | Oct 1997 | A |
5676662 | Fleischhacker et al. | Oct 1997 | A |
5676692 | Sanghvi et al. | Oct 1997 | A |
5676693 | LaFontaine | Oct 1997 | A |
5678550 | Bassen et al. | Oct 1997 | A |
5680860 | Imran | Oct 1997 | A |
5681278 | Igo et al. | Oct 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5687723 | Avitall | Nov 1997 | A |
5687737 | Branham et al. | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5690611 | Swartz et al. | Nov 1997 | A |
5697281 | Eggers et al. | Dec 1997 | A |
5697536 | Eggers et al. | Dec 1997 | A |
5697882 | Eggers et al. | Dec 1997 | A |
5697909 | Eggers et al. | Dec 1997 | A |
5697925 | Taylor | Dec 1997 | A |
5697927 | Imran et al. | Dec 1997 | A |
5697928 | Walcott et al. | Dec 1997 | A |
5713942 | Stern et al. | Feb 1998 | A |
5716389 | Walinsky et al. | Feb 1998 | A |
5718241 | Ben-Haim et al. | Feb 1998 | A |
5718701 | Shai et al. | Feb 1998 | A |
5720775 | Larnard | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5725524 | Mulier et al. | Mar 1998 | A |
5730074 | Peter | Mar 1998 | A |
5730127 | Avitall | Mar 1998 | A |
5730704 | Avitall | Mar 1998 | A |
5733280 | Avitall | Mar 1998 | A |
5733281 | Nardella | Mar 1998 | A |
5735280 | Sherman et al. | Apr 1998 | A |
5735290 | Sterman et al. | Apr 1998 | A |
5749869 | Lindenmeier et al. | May 1998 | A |
5755760 | Maguire et al. | May 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5782828 | Chen et al. | Jul 1998 | A |
5785706 | Bednarek | Jul 1998 | A |
5788636 | Curley | Aug 1998 | A |
5792140 | Tu et al. | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800428 | Nelson et al. | Sep 1998 | A |
5800482 | Pemeranz et al. | Sep 1998 | A |
5807395 | Mulier et al. | Sep 1998 | A |
5810802 | Panescu et al. | Sep 1998 | A |
5827216 | Igo et al. | Oct 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5840030 | Ferek-Petric et al. | Nov 1998 | A |
5844349 | Oakley et al. | Dec 1998 | A |
5846187 | Wells et al. | Dec 1998 | A |
5846191 | Wells et al. | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5860951 | Eggers et al. | Jan 1999 | A |
5868739 | Lindènmeier et al. | Feb 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5871525 | Edwards et al. | Feb 1999 | A |
5873845 | Cline et al. | Feb 1999 | A |
5876357 | Tomer | Mar 1999 | A |
5876398 | Mulier et al. | Mar 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5879295 | Li et al. | Mar 1999 | A |
5879296 | Ockuly et al. | Mar 1999 | A |
5881732 | Sung et al. | Mar 1999 | A |
5882346 | Pomeranz et al. | Mar 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5888198 | Eggers et al. | Mar 1999 | A |
5891095 | Eggers et al. | Apr 1999 | A |
5893848 | Negus et al. | Apr 1999 | A |
5895417 | Pomeranz et al. | Apr 1999 | A |
5897553 | Mulier et al. | Apr 1999 | A |
5897554 | Chia et al. | Apr 1999 | A |
5899898 | Arless et al. | May 1999 | A |
5899899 | Arless et al. | May 1999 | A |
5902289 | Swartz et al. | May 1999 | A |
5902328 | LaFontaine et al. | May 1999 | A |
5904711 | Flom et al. | May 1999 | A |
5906580 | Kline-Schoder et al. | May 1999 | A |
5906587 | Zimmon | May 1999 | A |
5906606 | Chee et al. | May 1999 | A |
5906613 | Mulier et al. | May 1999 | A |
5908029 | Knudson et al. | Jun 1999 | A |
5913854 | Maguire et al. | Jun 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5916214 | Cosio et al. | Jun 1999 | A |
5921924 | Avitall | Jul 1999 | A |
5921982 | Lesh et al. | Jul 1999 | A |
5927284 | Borst et al. | Jul 1999 | A |
5928191 | Houser et al. | Jul 1999 | A |
5931810 | Grabek | Aug 1999 | A |
5931848 | Saadat | Aug 1999 | A |
5954661 | Greenspon et al. | Sep 1999 | A |
5971980 | Sherman | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5976128 | Schilling et al. | Nov 1999 | A |
5993447 | Blewett et al. | Nov 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6012457 | Lesh | Jan 2000 | A |
6016811 | Knopp et al. | Jan 2000 | A |
6042556 | Beach et al. | Mar 2000 | A |
6063081 | Mulier | May 2000 | A |
6071279 | Whayne et al. | Jun 2000 | A |
6083223 | Baker | Jul 2000 | A |
6088894 | Oakley | Jul 2000 | A |
6096037 | Mulier et al. | Aug 2000 | A |
6113592 | Taylor | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120496 | Whayne et al. | Sep 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6142994 | Swanson et al. | Nov 2000 | A |
6152920 | Thompson et al. | Nov 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6165174 | Jacobs et al. | Dec 2000 | A |
6216704 | Ingle et al. | Apr 2001 | B1 |
6217528 | Koblish et al. | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6231518 | Grabek et al. | May 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6235027 | Herzon | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6238347 | Nix et al. | May 2001 | B1 |
6238393 | Mulier | May 2001 | B1 |
6245061 | Panescu et al. | Jun 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6251092 | Qin et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6270471 | Hechel et al. | Aug 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6296619 | Brisken et al. | Oct 2001 | B1 |
6302880 | Schaer | Oct 2001 | B1 |
6311692 | Vaska et al. | Nov 2001 | B1 |
6312383 | Lizzi et al. | Nov 2001 | B1 |
6314962 | Vaska et al. | Nov 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6328736 | Mulier | Dec 2001 | B1 |
6332881 | Carner et al. | Dec 2001 | B1 |
6358248 | Mulier | Mar 2002 | B1 |
6361531 | Hissong | Mar 2002 | B1 |
6364876 | Erb et al. | Apr 2002 | B1 |
6368275 | Sliwa et al. | Apr 2002 | B1 |
6371955 | Fuimaono et al. | Apr 2002 | B1 |
6383151 | Diederich et al. | May 2002 | B1 |
6385472 | Hall et al. | May 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6409722 | Hoey | Jun 2002 | B1 |
6413254 | Hissong et al. | Jul 2002 | B1 |
6419648 | Vitek et al. | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6430426 | Avitall | Aug 2002 | B2 |
6440130 | Mulier | Aug 2002 | B1 |
6443952 | Mulier | Sep 2002 | B1 |
6447507 | Bednarek et al. | Sep 2002 | B1 |
6461314 | Pant et al. | Oct 2002 | B1 |
6461356 | Patterson | Oct 2002 | B1 |
6464700 | Koblish et al. | Oct 2002 | B1 |
6471697 | Lesh | Oct 2002 | B1 |
6471698 | Edwards et al. | Oct 2002 | B1 |
6474340 | Vaska et al. | Nov 2002 | B1 |
6475216 | Mulier | Nov 2002 | B2 |
6477396 | Mest et al. | Nov 2002 | B1 |
6484727 | Vaska et al. | Nov 2002 | B1 |
6488680 | Francischelli et al. | Dec 2002 | B1 |
6502575 | Jacobs et al. | Jan 2003 | B1 |
6514250 | Jahns | Feb 2003 | B1 |
6527767 | Wang et al. | Mar 2003 | B2 |
6537248 | Mulier | Mar 2003 | B2 |
6537272 | Christopherson et al. | Mar 2003 | B2 |
6558382 | Jahns | May 2003 | B2 |
6562037 | Paton et al. | May 2003 | B2 |
6582451 | Marucci et al. | Jun 2003 | B1 |
6584360 | Francischelli et al. | Jun 2003 | B2 |
6585732 | Mulier | Jul 2003 | B2 |
6605084 | Acker et al. | Aug 2003 | B2 |
6610055 | Swanson et al. | Aug 2003 | B1 |
6610060 | Mulier | Aug 2003 | B2 |
6613048 | Mulier | Sep 2003 | B2 |
6645199 | Jenkins et al. | Nov 2003 | B1 |
6648883 | Francischelli et al. | Nov 2003 | B2 |
6656175 | Francischelli | Dec 2003 | B2 |
6660001 | Gregory | Dec 2003 | B2 |
6663627 | Francischelli | Dec 2003 | B2 |
6692450 | Coleman | Feb 2004 | B1 |
6699240 | Francischelli | Mar 2004 | B2 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6706038 | Francischelli et al. | Mar 2004 | B2 |
6706039 | Mulier | Mar 2004 | B2 |
6716211 | Mulier | Apr 2004 | B2 |
6736810 | Hoey | May 2004 | B2 |
6755827 | Mulier | Jun 2004 | B2 |
6764487 | Mulier | Jul 2004 | B2 |
6773433 | Stewart et al. | Aug 2004 | B2 |
6776780 | Mulier | Aug 2004 | B2 |
6807968 | Francischelli | Oct 2004 | B2 |
6827715 | Francischelli | Dec 2004 | B2 |
6849073 | Hoey | Feb 2005 | B2 |
6858028 | Mulier | Feb 2005 | B2 |
6887238 | Jahns | May 2005 | B2 |
6899711 | Stewart et al. | May 2005 | B2 |
6911019 | Mulier | Jun 2005 | B2 |
6916318 | Francischelli | Jul 2005 | B2 |
6936046 | Hissong | Aug 2005 | B2 |
6949097 | Stewart et al. | Sep 2005 | B2 |
6949098 | Mulier | Sep 2005 | B2 |
6960205 | Jahns | Nov 2005 | B2 |
6962589 | Mulier | Nov 2005 | B2 |
7025764 | Paton et al. | Apr 2006 | B2 |
7267677 | Johnson et al. | Sep 2007 | B2 |
20010039417 | Harano et al. | Nov 2001 | A1 |
20020052599 | Goble | May 2002 | A1 |
20020091384 | Hooven et al. | Jul 2002 | A1 |
20020091385 | Paton et al. | Jul 2002 | A1 |
20020120267 | Phan | Aug 2002 | A1 |
20030018329 | Hooven | Jan 2003 | A1 |
20030045872 | Jacobs | Mar 2003 | A1 |
20030144656 | Ocel | Jul 2003 | A1 |
20030171745 | Francischelli et al. | Sep 2003 | A1 |
20030191462 | Jacobs | Oct 2003 | A1 |
20030195384 | Francischelli et al. | Oct 2003 | A1 |
20030199869 | Johnson et al. | Oct 2003 | A1 |
20030216724 | Jahns | Nov 2003 | A1 |
20040015106 | Coleman | Jan 2004 | A1 |
20040015219 | Francischelli | Jan 2004 | A1 |
20040044340 | Francischelli | Mar 2004 | A1 |
20040049179 | Francischelli | Mar 2004 | A1 |
20040078069 | Francischelli | Apr 2004 | A1 |
20040082948 | Stewart et al. | Apr 2004 | A1 |
20040087940 | Jahns | May 2004 | A1 |
20040092926 | Hoey | May 2004 | A1 |
20040138621 | Jahns | Jul 2004 | A1 |
20040138656 | Francischelli | Jul 2004 | A1 |
20040143260 | Francischelli | Jul 2004 | A1 |
20040143263 | Schechter et al. | Jul 2004 | A1 |
20040186465 | Francischelli | Sep 2004 | A1 |
20040215183 | Hoey | Oct 2004 | A1 |
20040220560 | Briscoe | Nov 2004 | A1 |
20040236322 | Mulier | Nov 2004 | A1 |
20040267252 | Washington et al. | Dec 2004 | A1 |
20040267326 | Ocel | Dec 2004 | A1 |
20050010095 | Stewart et al. | Jan 2005 | A1 |
20050033278 | McClurken et al. | Feb 2005 | A1 |
20050033280 | Francischelli | Feb 2005 | A1 |
20050090815 | Francischelli | Apr 2005 | A1 |
20050113828 | Shields et al. | May 2005 | A1 |
20050143729 | Francischelli | Jun 2005 | A1 |
20050165392 | Francischelli | Jul 2005 | A1 |
20050209564 | Bonner | Sep 2005 | A1 |
20050256522 | Francischelli et al. | Nov 2005 | A1 |
20050267454 | Hissong | Dec 2005 | A1 |
20060009756 | Francischelli | Jan 2006 | A1 |
20060009759 | Chrisitian | Jan 2006 | A1 |
Number | Date | Country |
---|---|---|
03-020139 | Mar 2003 | WO |
03-090630 | Nov 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20050256522 A1 | Nov 2005 | US |